The University of Southampton
University of Southampton Institutional Repository

Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT

Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT

Background: there has been a steady increase in the number of primary care patients receiving long-term maintenance antidepressant treatment, despite limited evidence of a benefit of this treatment beyond 8 months.

Objective: the ANTidepressants to prevent reLapse in dEpRession (ANTLER) trial investigated the clinical effectiveness and cost-effectiveness of antidepressant medication in preventing relapse in UK primary care.

Design: this was a Phase IV, double-blind, pragmatic, multisite, individually randomised parallel-group controlled trial, with follow-up at 6, 12, 26, 39 and 52 weeks. Participants were randomised using minimisation on centre, type of antidepressant and baseline depressive symptom score above or below the median using Clinical Interview Schedule - Revised (two categories). Statisticians were blind to allocation for the outcome analyses.

Setting: general practices in London, Bristol, Southampton and York.

Participants: individuals aged 18-74 years who had experienced at least two episodes of depression and had been taking antidepressants for ≥ 9 months but felt well enough to consider stopping their medication. Those who met an International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, diagnosis of depression or with other psychiatric conditions were excluded.

Intervention: at baseline, participants were taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg. They were randomised to either remain on their current medication or discontinue medication after a tapering period.

Main outcome measures: the primary outcome was the time, in weeks, to the beginning of the first depressive episode after randomisation. This was measured by a retrospective Clinical Interview Schedule - Revised that assessed the onset of a depressive episode in the previous 12 weeks, and was conducted at 12, 26, 39 and 52 weeks. The depression-related resource use was collected over 12 months from medical records and patient-completed questionnaires. Quality-adjusted life-years were calculated using the EuroQol-5 Dimensions, five-level version.

Results: between 9 March 2017 and 1 March 2019, we randomised 238 participants to antidepressant continuation (the maintenance group) and 240 participants to antidepressant discontinuation (the discontinuation group). The time to relapse of depression was shorter in the discontinuation group, with a hazard ratio of 2.06 (95% confidence interval 1.56 to 2.70; p < 0.0001). By 52 weeks, relapse was experienced by 39% of those who continued antidepressants and 56% of those who discontinued antidepressants. The secondary analysis revealed that people who discontinued experienced more withdrawal symptoms than those who remained on medication, with the largest difference at 12 weeks. In the discontinuation group, 37% (95% confidence interval 28% to 45%) of participants remained on their randomised medication until the end of the trial. In total, 39% (95% confidence interval 32% to 45%) of participants in the discontinuation group returned to their original antidepressant compared with 20% (95% confidence interval 15% to 25%) of participants in maintenance group. The health economic evaluation demonstrated that participants randomised to discontinuation had worse utility scores at 3 months (-0.037, 95% confidence interval -0.059 to -0.015) and fewer quality-adjusted life-years over 12 months (-0.019, 95% confidence interval -0.035 to -0.003) than those randomised to continuation. The discontinuation pathway, besides giving worse outcomes, also cost more [extra £2.71 per patient over 12 months (95% confidence interval -£36.10 to £37.07)] than the continuation pathway, although the cost difference was not significant.

Conclusions: patients who discontinue long-term maintenance antidepressants in primary care are at increased risk of relapse and withdrawal symptoms. However, a substantial proportion of patients can discontinue antidepressants without relapse. Our findings will give patients and clinicians an estimate of the likely benefits and harms of stopping long-term maintenance antidepressants and improve shared decision-making. The participants may not have been representative of all people on long-term maintenance treatment and we could study only a restricted range of antidepressants and doses. Identifying patients who will not relapse if they discontinued antidepressants would be clinically important.

Trial registration: current Controlled Trials ISRCTN15969819 and EudraCT 2015-004210-26.

Funding: this project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 69. See the NIHR Journals Library website for further project information.

ANTIDEPRESSANT, DEPRESSION, MAINTENANCE TREATMENT, PRIMARY CARE, RCT, RELAPSE, SSRI
1366-5278
Duffy, Larisa
68ab154c-9825-44ad-8385-b3dcadf30651
Clarke, Caroline S.
758a73e6-b89d-4c39-bf61-928bee596728
Lewis, Gemma
736f9361-ca4d-4347-bc75-18d21fda5052
Marston, Louise
258cc87f-2cf7-49de-9498-fc659a5ffde7
Freemantle, Nick
8182a4ad-e20e-4aea-b5f7-62b170845d1e
Gilbody, Simon
6d135882-a8df-444c-85aa-980dddef45a5
Hunter, Rachael
155068d4-d49a-4180-8eb0-0c549aa7f95c
Kendrick, Tony
c697a72c-c698-469d-8ac2-f00df40583e5
Kessler, David
3659e526-e667-46cb-bd9c-02bce7d58d41
King, Michael
cf8c59d9-802d-45b8-8413-be0d41446c0d
Lanham, Paul
2bcf9c17-6c36-47a1-8714-3bc984ae4406
Mangin, Dee
911e4c3d-2444-4fb1-bd08-5fb1b54ce359
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Nazareth, Irwin
630042a9-f574-448d-85fa-d2ac3a6807b5
Wiles, Nicola
fcec2769-de78-4b86-b9c1-eab754a02837
Bacon, Faye
2ad97865-e909-4bff-8f55-be8f2b8d4e6b
Bird, Molly
feff531c-b7d7-4971-a01b-469604a77403
Brabyn, Sally
aae0a41d-5239-46e8-a5d5-a54809f7afb2
Burns, Alison
19b259cc-41ea-45e3-9f0b-0c64bb30899c
Donkor, Yvonne
e01e4992-1de4-4ff2-99bd-3ad4698c3417
Hunt, Anna
a31770b6-70ab-4639-b870-d55aab72d299
Pervin, Jodi
e38fcf4b-d7b3-4834-ad46-a38741ba60cf
Lewis, Glyn
11aed8f6-3905-455e-8e89-34147a5e5d26
Duffy, Larisa
68ab154c-9825-44ad-8385-b3dcadf30651
Clarke, Caroline S.
758a73e6-b89d-4c39-bf61-928bee596728
Lewis, Gemma
736f9361-ca4d-4347-bc75-18d21fda5052
Marston, Louise
258cc87f-2cf7-49de-9498-fc659a5ffde7
Freemantle, Nick
8182a4ad-e20e-4aea-b5f7-62b170845d1e
Gilbody, Simon
6d135882-a8df-444c-85aa-980dddef45a5
Hunter, Rachael
155068d4-d49a-4180-8eb0-0c549aa7f95c
Kendrick, Tony
c697a72c-c698-469d-8ac2-f00df40583e5
Kessler, David
3659e526-e667-46cb-bd9c-02bce7d58d41
King, Michael
cf8c59d9-802d-45b8-8413-be0d41446c0d
Lanham, Paul
2bcf9c17-6c36-47a1-8714-3bc984ae4406
Mangin, Dee
911e4c3d-2444-4fb1-bd08-5fb1b54ce359
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Nazareth, Irwin
630042a9-f574-448d-85fa-d2ac3a6807b5
Wiles, Nicola
fcec2769-de78-4b86-b9c1-eab754a02837
Bacon, Faye
2ad97865-e909-4bff-8f55-be8f2b8d4e6b
Bird, Molly
feff531c-b7d7-4971-a01b-469604a77403
Brabyn, Sally
aae0a41d-5239-46e8-a5d5-a54809f7afb2
Burns, Alison
19b259cc-41ea-45e3-9f0b-0c64bb30899c
Donkor, Yvonne
e01e4992-1de4-4ff2-99bd-3ad4698c3417
Hunt, Anna
a31770b6-70ab-4639-b870-d55aab72d299
Pervin, Jodi
e38fcf4b-d7b3-4834-ad46-a38741ba60cf
Lewis, Glyn
11aed8f6-3905-455e-8e89-34147a5e5d26

Duffy, Larisa, Clarke, Caroline S., Lewis, Gemma, Marston, Louise, Freemantle, Nick, Gilbody, Simon, Hunter, Rachael, Kendrick, Tony, Kessler, David, King, Michael, Lanham, Paul, Mangin, Dee, Moore, Michael, Nazareth, Irwin, Wiles, Nicola, Bacon, Faye, Bird, Molly, Brabyn, Sally, Burns, Alison, Donkor, Yvonne, Hunt, Anna, Pervin, Jodi and Lewis, Glyn (2021) Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT. Health technology assessment (Winchester, England), 25 (69). (doi:10.3310/hta25690).

Record type: Article

Abstract

Background: there has been a steady increase in the number of primary care patients receiving long-term maintenance antidepressant treatment, despite limited evidence of a benefit of this treatment beyond 8 months.

Objective: the ANTidepressants to prevent reLapse in dEpRession (ANTLER) trial investigated the clinical effectiveness and cost-effectiveness of antidepressant medication in preventing relapse in UK primary care.

Design: this was a Phase IV, double-blind, pragmatic, multisite, individually randomised parallel-group controlled trial, with follow-up at 6, 12, 26, 39 and 52 weeks. Participants were randomised using minimisation on centre, type of antidepressant and baseline depressive symptom score above or below the median using Clinical Interview Schedule - Revised (two categories). Statisticians were blind to allocation for the outcome analyses.

Setting: general practices in London, Bristol, Southampton and York.

Participants: individuals aged 18-74 years who had experienced at least two episodes of depression and had been taking antidepressants for ≥ 9 months but felt well enough to consider stopping their medication. Those who met an International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, diagnosis of depression or with other psychiatric conditions were excluded.

Intervention: at baseline, participants were taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg. They were randomised to either remain on their current medication or discontinue medication after a tapering period.

Main outcome measures: the primary outcome was the time, in weeks, to the beginning of the first depressive episode after randomisation. This was measured by a retrospective Clinical Interview Schedule - Revised that assessed the onset of a depressive episode in the previous 12 weeks, and was conducted at 12, 26, 39 and 52 weeks. The depression-related resource use was collected over 12 months from medical records and patient-completed questionnaires. Quality-adjusted life-years were calculated using the EuroQol-5 Dimensions, five-level version.

Results: between 9 March 2017 and 1 March 2019, we randomised 238 participants to antidepressant continuation (the maintenance group) and 240 participants to antidepressant discontinuation (the discontinuation group). The time to relapse of depression was shorter in the discontinuation group, with a hazard ratio of 2.06 (95% confidence interval 1.56 to 2.70; p < 0.0001). By 52 weeks, relapse was experienced by 39% of those who continued antidepressants and 56% of those who discontinued antidepressants. The secondary analysis revealed that people who discontinued experienced more withdrawal symptoms than those who remained on medication, with the largest difference at 12 weeks. In the discontinuation group, 37% (95% confidence interval 28% to 45%) of participants remained on their randomised medication until the end of the trial. In total, 39% (95% confidence interval 32% to 45%) of participants in the discontinuation group returned to their original antidepressant compared with 20% (95% confidence interval 15% to 25%) of participants in maintenance group. The health economic evaluation demonstrated that participants randomised to discontinuation had worse utility scores at 3 months (-0.037, 95% confidence interval -0.059 to -0.015) and fewer quality-adjusted life-years over 12 months (-0.019, 95% confidence interval -0.035 to -0.003) than those randomised to continuation. The discontinuation pathway, besides giving worse outcomes, also cost more [extra £2.71 per patient over 12 months (95% confidence interval -£36.10 to £37.07)] than the continuation pathway, although the cost difference was not significant.

Conclusions: patients who discontinue long-term maintenance antidepressants in primary care are at increased risk of relapse and withdrawal symptoms. However, a substantial proportion of patients can discontinue antidepressants without relapse. Our findings will give patients and clinicians an estimate of the likely benefits and harms of stopping long-term maintenance antidepressants and improve shared decision-making. The participants may not have been representative of all people on long-term maintenance treatment and we could study only a restricted range of antidepressants and doses. Identifying patients who will not relapse if they discontinued antidepressants would be clinically important.

Trial registration: current Controlled Trials ISRCTN15969819 and EudraCT 2015-004210-26.

Funding: this project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 69. See the NIHR Journals Library website for further project information.

Text
3038159 - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Published date: 1 November 2021
Additional Information: Fully NIHR publication
Keywords: ANTIDEPRESSANT, DEPRESSION, MAINTENANCE TREATMENT, PRIMARY CARE, RCT, RELAPSE, SSRI

Identifiers

Local EPrints ID: 452827
URI: http://eprints.soton.ac.uk/id/eprint/452827
ISSN: 1366-5278
PURE UUID: 2bd5ac04-39c0-4c07-81ff-6f4e61631b7e
ORCID for Tony Kendrick: ORCID iD orcid.org/0000-0003-1618-9381
ORCID for Michael Moore: ORCID iD orcid.org/0000-0002-5127-4509

Catalogue record

Date deposited: 21 Dec 2021 17:50
Last modified: 28 Apr 2022 01:54

Export record

Altmetrics

Contributors

Author: Larisa Duffy
Author: Caroline S. Clarke
Author: Gemma Lewis
Author: Louise Marston
Author: Nick Freemantle
Author: Simon Gilbody
Author: Rachael Hunter
Author: Tony Kendrick ORCID iD
Author: David Kessler
Author: Michael King
Author: Paul Lanham
Author: Dee Mangin
Author: Michael Moore ORCID iD
Author: Irwin Nazareth
Author: Nicola Wiles
Author: Faye Bacon
Author: Molly Bird
Author: Sally Brabyn
Author: Alison Burns
Author: Yvonne Donkor
Author: Anna Hunt
Author: Jodi Pervin
Author: Glyn Lewis

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×